Cyclosporin maintenance monotherapy after renal transplantation: What factors predict success?

BioDrugs

Volumn 12, Issue 2, 1999, Pages 91-113

  Touchard, Guy ^a,b   Verove, Cathy ^a   Bridoux, Frank ^a   Bauwens, Marc ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b University of Poitiers   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; STEROID;

ADULT; AGE; ARTICLE; CANCER RISK; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032820113     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199912020-00002     Document Type: Article

References (84)

1. Salaman JR, Cyclosporin mono-drug therapy. Transplant Proc 1988; 20: 117-20
2. Salaman JR. Low dose cyclosporine monotherapy v. combination therapies. In: Touraine, JL. Transplantation and Clinical Immunology 1989. Amsterdam: Elsevier, 1989: 73-84
3. Salaman JR. Cyclosporine monotherapy - Who needs it? Clin Exp Perspect Sandimmun Ther 1991; 1: 1-4
4. Schleibner S, Schnecberger H, Hillebrand G, et al. Cyclosporine monotherapy. An ideal long term immunosuppression? Transplant Proc 1990; 22: 1695-6
5. Tarantino A, Aroldi A, Stucchi L, et al. A randomized prospective trial comparing cyclosporine monotherapy with triple drug therapy in renal transplantation. Transplantation 1991; 52: 53-7
6. Tamm M, Thiel G, Huser B, et al. Cyclosporine monotherapy after kidney transplantation since 1983. Transplant Proc 1991; 23: 997-8
7. Thiel G, Bock A. Spondlin M, et al. Long term benefits and risks of cyclosporine A (Sandimmune). An analysis at 10 years. Transplant Proc 1994; 26: 2493-8
8. Park K, Kim ST, Lee SR, et al. A 1-year prospective randomized study in Korean living donor kidney transplant recipients: Comparing cyclosporine monotherapy and cyclosporine/prednisolone during the maintenance phase of immunosuppression. Transplant Proc 1994; 26: 1985-6
9. Margreiter R, Bösmüller C, Spielberger M, et al. Cyclosporine monotherapy after cadaveric renal transplantation. Transplant Proc 1989; 11: 1591-3
10. Morales JM, Munoz Cepada MA, Sancho S, et al. Cyclosporine (cya) alone as therapy of maintenance in renal transplants (rt) patients over fifty years old: A prospective study [abstract]. J Am Soc Nephrol 1991; 2: 509
11. Morales JM, Sancho S, Munoz MA, et al. Cyclosporine monotherapy in patients over 50 years of age after renal transplantation: Short term results. Transplant Proc 1992; 24: 37-8
12. Johnson RWG, Mallick NP, Scott PD, et al. Prospective trials with cyclosporine monotherapy in cadaver renal transplantation. J Nephrol 1990; 4: 47-9
13. Johnson RWG. Primary regimens in immunosuppression. Nephrol Dial Transplant 1995; 10: 101-4
14. Griffin PJA. Rose WB, Williams JD, et al. Low dose cyclosporine monotherapy in renal transplantation. Transplant Proc 1987; 5: 3685
15. Griffin PJA, Salaman JR. Long term results of cyclosporine monotherapy in kidney transplantation. Transplant Proc 1991; 23: 992-3
16. Opelz G, Collaborative Transplant Study. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 1994; 58: 443-6
17. Bertoni E, Zanazzi M, Rosati A, et al. Long term steroid side effects in renal transplantation need a safe steroid withdrawal: A single-center experience. Transplant Proc 1998; 30: 1303-4
18. Gulanikar AC, Belistky P, MacDonald AS, et al. Randomized controlled trial of steroids versus non steroids in stable cyclosporine-treated renal graft recipients. Transplant Proc 1991; 23: 990
19. Johnson RWG, Mallick NP, Bakran A, et al. Cadaver renal transplantation without maintenance steroids. Transplant Proc 1989; 21: 1581-2
20. Lloveras J, Puig JM, Comerma I, et al. Requirements for safe prednisolone discontinuation in late renal transplantation in recipients immunosuppressed with cyclosporine. Transplant Proc 1990; 22: 1693-4
21. Maiorca R, Cristinelli L, Brunori G, et al. Prospective controlled trial of steroid withdrawal after six months in renal transplant patients treated with cyclosporine. Transplant Proc 1988; 20 Suppl. 3: 121-5
22. Stratta RJ, Armbrust MJ, Oh CS, et al. Withdrawal of steroid immunosuppression in renal transplant patients. Transplantation 1988; 45: 323
23. Stratta RJ. Experience with azathioprine withdrawal after simultaneous kidney-pancreas transplantation. Transplant Proc 1998; 30: 1353-4
24. Hegner I, Binswanger U, Cyclosporine A monotherapy compared to azathioprine: Cyclosporine A double therapy in long term immunosuppression after kidney allotransplantation [abstract]. Kidney Int 1995; 47: 975
25. Touchard G, Cogny F, Hurault de Ligny B, et al. Maintenance cyclosporine monotherapy in primary cadaver renal transplants. Results of a French collaborative group study: Angers, Caen, Limoges, Poitiers, Reims, Tours [abstract]. J Am Soc Nephrol 1991; 2, 820
26. Touchard G, Hauet T, Cogny Van Weydevelt F, et al. Maintenance cyclosporine A monotherapy in primary cadaver renal transplant: Complementary results of a multicentric study. Kidney Int 1994; 46: 1242-3
27. Kupin W, Venkat KK, Oh HK, et al. Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients. Transplantation 1988; 45: 53-5
28. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on post transplant hypercholesterolemia. Am J Kidney Dis 1991; 18: 353
29. Hricik DE, Whalen CC, Lautman J, et al. Withdrawal of steroids after renal transplantation. Clinical predictors of outcome. Transplantation 1992; 53: 41-5
30. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on postransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991; 51: 374
31. Ponticelli C, Tarantino A, Segaloni GP, et al. Italian multicentre study group for renal transplantation. A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation. J Am Soc Nephrol 1997; 8: 638-46
32. Tejani A, Khalid MH, Rajpoot D, et al. Strategies for optimizing growth in children with kidney transplants. Transplantation 1989; 47: 229
33. Reisman I., Lieberman KV, Burrows L, et al. Follow-up cyclosporine treated pediatric renal allograft recipients after cessation of prednisone. Transplantation 1990; 49: 76
34. Wolpaw TM, Deal CL, Fleming-Brooks S, et al. Factors influencing vertebral bone density after renal transplantation. Transplantation 1994; 58: 1186
35. Hricik DE, O'Toole MA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: A meta-analysis. J Am Soc Nephrol 1993; 4: 130
36. Hricik DE. Steroid withdrawal in renal transplant recipients: Pro point of view. Transplant Proc 1998; 30: 1380-2
37. Ponticelli C, Opelz G. Are corticosteroids really necessary in renal transplantation? Nephrol Dial Transplant 1995; 10: 1587-91
38. Brown MW, Forwell MA. Rejection reaction after stopping prednisolone in kidney transplant recipients taking cyclosporine. N Engl J Med 1986; 314: 183
39. Opelz G. Superior long term kidney graft survival in patients on maintenance immunosuppression with cyclosporine and azathioprine. Transplant Proc 1993; 25: 1289-90
40. Bouma GD, Hollander DAMJ, Van Der Meer-Prins, et al. In vitro sensitivity to prednisolone may predict kidney rejection after steroid withdrawal. Transplantation 1996; 62: 1422-9
41. Touchard G, Hauet T, Cogny Van Weydevelt F, et al. Maintenance cyclosporine monotherapy after renal transplantation: Clinical predictors of long term outcome. Nephrol Dial Transplant 1997; 12: 1956-60
42. Hurault de Ligny B, Toupance O, Lavaud S, et al. Facteurs prédictifs de succès à long terme de la cyclosporine en monothérapie d'entretien après transplantation rénale [abstract]. Ler Congrès Francophone de Recherche Clinique et Biologique en Transplantation. 1996 Dec 5-6, Paris
43. Goldman MH, Davis B, Cruz E., et al. Effects of azathioprine withdrawal in kidney recipients with stable function two years after transplant. Clin Tansplant 1996; 10: 617-9
44. Schneeberger H, Zanker b, Hillebrand G, et al. Tacrolimus as a primary immunosuppressive therapy in cadaveric renal transplantation: Five years' experience at a single center. Transplant Proc 1998; 30: 1598-9
45. Shapiro R, Jordan ML, Scantlebury VP, et al. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppresion. Transplant Proc 1998; 30: 1375-7
46. Grewal HP, Thistlethwhite JR, Loss GE. et al. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. Transplant Proc 1998; 30: 1378-9
47. Calne RY, Wood AJ, Cyclosporine in cadaveric renal transplantation: 3 Year follow-up of a European multicentre trial. Lancet 1985; 11: 549
48. Hillebrand G, Schneeberger H, Schleibner S, et al. Ten years experience with cyclosporine monotherapy after renal transplantation. Transplant Proc 1993; 25: 513-4
49. Land W, Cyclosporine in cadaveric renal transplantation: Five years follow up results of the European multicentre trial. Transplant Proc 1988; 20: 73-84
50. Hurault de Ligny B, Toupance O, Lavaud S. et al. Factors predicting the long term success of maintenance cyclosporine monotherapy after kidney transplantation. Transplantation. In press
51. Terasaki PI. Ed. UCLA Tissue Typing Laboratory, Los Angeles, Californa. Clinical Transplants 1988; 409-33
52. Wang H, Solez K, Kjellstrand CM, et al. The importance of donor vascular pathology in determining renal allograft outcome [abstract]. J Am Soc Nephrol 1998; 9: 702A
53. Andreu J, Campistol JM, Oppenheimer F, et al. Monotherapy with cyclosporine in kidney transplantation. Transplant Proc 1990; 22: 2270-1
54. Andreu J, Campistol JM, Oppenheimer F, et al. Cyclosporine monotherapy as primary immunosuppression in renal transplantation. Five year experience. Transplant Proc 1994; 26: 337-40
55. Opelz G. CTS Collaborative Transplant Study Newsletter 1996: 5
56. Ratcliffe PJ, Dudley CRK, Pirth JD, et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643-8
57. Ben-Maimon CS, Burke JF, Besarab A, et al. Evidence against chronic progressive cyclosporine nephrotoxicity. Transplant Proc 1991; 23: 1260-2
58. Burke JF, Pirsch JD, Ramos EL, et al. Long term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 1994; 331: 358-63
59. Lewis RM. Long term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Kidney Int 1995; 48: S75-8
60. Aikawa A, Sells RA, Ward RG, et al. Retrospective study of renal transplantation with cyclosporine monotherapy. Transplant Proc 1992; 24: 1694-5
61. Opelz G. Collaborative Transplant Study Newsletter 1993; 4
62. Griffin PJA, Ferguson CJ, Ross WB, et al. A controlled trial of azathioprine in combination with cyclosporine in cadaveric renal transplantation. Transplant Proc. 1990; 22: 1369
63. Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309: 809-15
64. Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. N Engl J Med 1986; 314: 1219-25
65. Gjertson DW, Cecka JM, Terasaki PL. The relative effects of FK506 and cyclosporine on short and long term kidney graft survival. Transplantation 1995; 60: 1384-8
66. Turka LA. What's new in transplant immunology: Problems and prospects. Ann Intern Med 1998; 128: 946-8
67. Hourmant M, Buzelin F, Dubigeon P, et al. High long term graft survival rates in kidney transplantation with the seqential association of antithymocyte globulin and cyclosporine A monotherapy. Transplant Proc 1987; 19: 2113-4
68. Klare B, Strom TM, Hahn H, et al. Remarkable long term prognosis and excellent growth in kidney transplant children under cyclosporine monotherapy. Transplant Proc 1991; 23: 1013-7
69. Arias M, Cereira P, Plazza JJ, et al. Cyclosporine monotherapy versus triple therapy in steady state renal transplant patients; cardiovascular risk factors (Multicentric Study) [abstract]. Kidney Int 1992; 44: 1424
70. Kiberd A, Cyclosporine-induced renal dysfunction in human renal allograft recipients. Transplantation 1989; 48: 965-9
71. Berg KJ, Holdaas H, Endresen L. et al. Effects of isradipine on renal function in cyclosporin-treated renal transplanted patients. Nephrol Dial Transplant 1991; 6: 725-30
72. Propper DJ, Whiting PH, Power DA, et al. The effect of nifedipine on graft function in renal allograft recipients treated with cyclosporine A. Clin Nephrol 1989; 32: 62-7
73. Murer L, Giacomini A, Gambaro G, et al. Long term treatment with CsA decreases INF-γmRNA and increases pre-pro-ET1 mRNA in rat kidneys. Transplant Proc 1998; 30: 950-1
74. Asberg A, Christensen H, Hartmann A, et al. Diltiazem modulates cyclosporin A induced renal hemodynamic effects but not its effect on plasma endothelin-I. Clin Transplant 1998; 12: 363-70
75. Kon V, Sugiura M, Inagami T. et al. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37: 1487-91
76. Provencher PH, Saltis J, Funder JW. Glucocorticoids but not mineralocorticoids modulate endothelin-I and angiotensin II binding in SHR vascular smooth muscle cells. J Steroid Biochem Mol Biol 1995; 52: 219-25
77. Stanimirovic DB, McCarron RM, Spatz M. Dexamethasone down-regulates endothelin receptors in human cerebro-microvascular endothelial cells. Neuropeptides 1994; 26: 145-52
78. Laporte J, D'Orleans-Juste P, Singh G, et al. Dexamethasone and phosphoramidon inhibit endothelin release by cultured nonciliated bronchiolar epithelial (Clara) cells. J Cardiovasc Pharmacol 1995; 26: S53-5
79. Calderon E, Gomez-Sanchez CE, Cozza EN, et al. Modulation of endothelin-I production by a pulmonary epithelial cell line. I. Regulation by glucocorticoids. Biochem Pharmacol 1994; 48: 2065-71
80. Vittori E, Marini M, Fasoli A, et al. Increased expression of endothelin in bronchial epithelial cells of asthmatic patients and effect of corticosteroids. Am Rev Respir Dis 1992; 146: 1320-5
81. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-I by cultured endothelial cells. J Biol Chem 1992; 267: 16066-8
82. Glover MT, Deeks JJ, Raftery MJ, et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997; 349: 398-9
83. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporine regimens. Lancet 1998; 351: 623-8
84. Confavreux C, Saddler P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: A case control study. Neurology 1996; 46: 1607-12